

### **INVESTOR PRESENTATION**

May 2023



# FORWARD-LOOKING STATEMENTS



This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those projected in the forward-looking statements. Examples of such forward-looking statements include but are not limited to: (i) statements regarding the Company's results of operations and financial condition; (ii) statements of plans, objectives or goals of the Company or its management, including those related to financing, products, or services; (iii) statements of future economic performance; and (iv) statements of assumptions underlying such statements. Words such as "believes," "anticipates," "expects," "intends," "forecasts," and "plans," and similar expressions are intended to identify forward-looking statements but are not the exclusive means of identifying such statements. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, and risks exist that the predictions, forecasts, projections, and other forward-looking statements will not be achieved. The Company cautions that several important factors could cause actual results to differ materially from the plans, objectives, expectations, estimates, and intentions expressed in such forward-looking statements. These factors include but are not limited to: (i) lower than expected future sales; (ii) increasing competitive industry pressures; (iii) general economic conditions or conditions affecting demand for the products and services it offers, both domestically and internationally, including as a result of post-Brexit regulation, being less favorable than expected; (iv) worldwide economic and business conditions and conditions in the industries in which the Company operates; (v) fluctuations in the cost of raw materials, utilities, and other inputs; (vi) currency fluctuations and hedging risks; (vii) the Company's ability to protect its intellectual property; (viii) the significant amount of indebtedness the Company has incurred and may incur and the obligations to service such indebtedness and to comply with the covenants contained therein; and (ix) risks related to the impact of the global COVID-19 pandemic, such as the scope and duration of the outbreak, government actions, and restrictive measures implemented in response thereto, supply chain disruptions and other impacts to the business, and the Company's ability to execute business continuity plans, as a result of the COVID-19 pandemic. The Company cautions that the foregoing list of important factors is not exhaustive. These factors are more fully discussed in the sections entitled "Forward-Looking Statements" and "Risk Factors" in its Annual Report on Form 10-K for the year ended December 31, 2022, which was filed with the U.S. Securities and Exchange Commission on March 1, 2023. When relying on forward-looking statements to make decisions with respect to the Company, investors and others should carefully consider the foregoing factors and other uncertainties and events. Forward-looking statements speak only as of the date on which they are made, and the Company does not undertake any obligation to update or revise any such statement, whether because of new information, future events, or otherwise.

# We are Luxfer

We help to create a safe, clean and energy efficient world

### LUXFER OVERVIEW (NYSE: LXFR)



4

#### **Company Description** Full Year 2022 Sales Breakdown Luxfer is a global industrial company innovating niche applications in materials engineering. Luxfer's highby End Market performance materials, components and high-pressure Defense, gas containment devices are used in defense and First emergency response, clean energy, healthcare, **Transportation Response &** 31% transportation and general industrial applications. Healthcare 32% **Company Snapshot** General \$411M Equity Market Capitalization<sup>1</sup> Industrial 37% Net Debt/Adj. EBITDA<sup>2</sup> 1.5x ROIC on Adj. Earnings<sup>2</sup> 13.3% by Geography **Income Statement** 2017 – 2022 Change Full Year 2022 Asia Pacific & Other Revenue<sup>3</sup> \$423M 4.0% CAGR 22% Adj. EBITDA<sup>23</sup> \$63M 2.0% CAGR **United States** 57% Adj. Diluted EPS<sup>2 3</sup> \$1.36 5.7% CAGR Europe 21% **Balance Sheet** 01 2023 Year End 2017 Net Debt \$90M \$101M

<sup>1</sup> As of May 1, 2023 <sup>2</sup> Non-GAAP numbers. Reconciliation in Appendix <sup>3</sup> Excludes the impact of Discontinued Operations

Global Industrial Company Innovating Niche Applications in Materials Engineering

CUSTOMER FIRST • INTEGRITY • ACCOUNTABILITY • INNOVATION • PERSONAL DEVELOPMENT • TEAMWORK

### **MATERIALS TECHNOLOGY LEADERSHIP**



Elektron	High Performance Magnesium Alloys	Innovation leader in the use of magnesium alloys for critical applications in aerospace, defense, and other industries as well as in flameless heating applications	MAGNESIUM ALLOYS
Segment	Specialty Zirconium Catalysts	Expertise in high-performance specialty zirconium-based solutions for a broad range of applications, including pharmaceuticals and electronics	ZIRCONIUM CATALYSTS
Gas Cylinders Segment	High Pressure Composite Cylinders	Trusted manufacturer of high- pressure composite and aluminum cylinders with high-performance, lightweight, and durable designs employed in a variety of specialized applications	<section-header></section-header>
Sales results as of Q1 2023.			

**Our Technology Expertise Drives Our Success** 

5

### **ALIGNED WITH SECULAR GROWTH TRENDS**





Clean Energy





Composite gas cylinders and systems used for Alternative Fuel applications, including Hydrogen and **Compressed Natural Gas** 

> Zirconium-based emissions control and industrial catalysis materials





Light





Lightweight carbon fiber cylinders for **breathing equipment** used by first responders

> Magnesium alloys for aerospace and automotive components





Safety, **Health & Technology** 



**Zirconium** in consumer technologies

Specialty magnesium and zirconium for pharmaceutical and medical applications



### **Significant Tailwinds for Growth**

# **QUARTERLY FINANCIAL HIGHLIGHTS**



(\$M except per share)

	Q1 2023	Q1 2022	Change
Sales	\$101.3	\$97.0	+4.4%
Adj. EBITDA Adj. EBITDA Margin	\$11.3 11.2%	\$16.1 16.6%	-29.8% -540bp
Adj. Diluted EPS	\$0.20	\$0.33	-39.4%

- Delivered quarterly EPS in line with guidance
- Sales rose 6.8% on constant currency basis
- Inflation offset by cost pass-through
- Volume/mix and increased legal expense weighed on EBITDA performance
- Lower order book year-over-year
- Expect sequential improvement in quarterly Sales and Adj. EPS in Q2



### Delivered 1Q 2023 Adj. EPS Objective

### OUR PATHWAY TO \$2.00 ADJ. EPS



#### 2023 Adj. EPS Guidance: Midpoint \$1.25



- ✓ Continuing current trajectory of Hydrogen growth
- ✓ Capitalize on Elektron new product introductions
- ✓ Expansion of Magtech Solutions defense offerings
- ✓ Normalization in European industrial market conditions
- Price stabilization in commodities and energy
- ✓ Recovery of prior inflationary costs
- Cylinders and Powders fixed cost savings initiatives
- ✓ Cessation of currently elevated legal costs
- ✓ Lower borrowing balances

#### Goal of \$2.00+ Adj. EPS in 2025

### BALANCED APPROACH TO CAPITAL DEPLOYMENT

Reinvestment in Organic Growth

- ✓ Reinforcing our existing strong capital position
- Investing thoughtfully in secular growth opportunities tied to niche materials engineering focus
- Identifying opportunities for new product innovation and operational efficiency

Return of Capital to Shareholders

> Select Bolt-on M&A

- ✓ Repurchased \$11.1M in shares during Full Year 2022
- Increased quarterly dividend 4% to \$0.13/share or \$0.52/share annualized in 2022
- Paid dividend since listing on the NYSE in 2012; more than \$136M returned to shareholders via dividend over that time
- ✓ **Disciplined approach to M&A,** supported by strong balance sheet
- Established process for evaluating **bolt-on acquisitions** to drive additional shareholder value

#### Balance Sheet Strength, Organic Growth, and Shareholder Returns

### **ENVIRONMENTAL, SOCIAL, AND GOVERNANCE ROADMAP**



#### **ENVIRONMENTAL**



- Committed to 20% reduction in CO2 emissions, 10% reduction in freshwater use, and 20% less waste to landfill by 2025
- Conducting Carbon Life Cycle Analyses to improve product sustainability
- Greener operations with more recycling; increasing use of renewable energy

#### SOCIAL



- Strong occupational health & safety record
- Expanded Diversity, Equity, and Inclusion (DEI) recruitment practices and training
- Supporting disaster relief efforts and local charitable programs
- Development program to cultivate next generation of firm's leaders

#### GOVERNANCE



- Robust corporate governance practices and Board-level oversight
- Implementing DFARS/NIST 800-171 IT Security Standard
- Rigorous compliance training program for employees

 $^{\rm 1}$  ISS QualityScores as of May 1, 2023

Behaving as a Strong Steward for All our Stakeholders

### **ADVANCING OUR GROWTH STRATEGY**



#### 2017-2020 **Growth Capabilities** Portfolio 2018-2023 Commercial Simplification 2023-2025 opportunities Cost **Transformation** Demand for Clean & Beyond Energy Organic and New products Inorganic Growth Growth talent Global presence Strong balance sheet Enhanced operating model

#### **Strong Foundation; Now Primed for Growth**

### THE "LUXFER BUSINESS SYSTEM"





- Implementing our new operating model: The Luxfer Business System
- A critical tool to realize growth potential embedded in our business
- Development led by key members of Luxfer's leadership team
- Emphasis on near-term execution and long-term investment to unlock sustainable growth

Driving Profitable Growth, Enabled by Our Business Excellence Model

# WELL POSITIONED FOR VALUE CREATION



We will help to create a safe, clean and energy-efficient world

 	Ø		-œ́-
Global Industrial Company	Attractive End Markets	Leading Return on Capital	Sustainable Growth
<ul> <li>✓ Market leading products</li> <li>✓ High-technology materials focus</li> <li>✓ Value-add niche applications</li> </ul>	<ul> <li>✓ Aligned with secular growth</li> <li>✓ Clean Energy</li> <li>✓ Light Weighting</li> <li>✓ Safety, Health &amp; Technology</li> </ul>	<ul> <li>✓ Strong balance sheet</li> <li>✓ Consistent cash conversion</li> <li>✓ Balanced capital allocation</li> <li>✓ Healthy margins</li> </ul>	<ul> <li>✓ Broad pipeline of new products</li> <li>✓ Compelling commercial opportunities</li> <li>✓ Committed to unlocking shareholder value</li> </ul>

#### There is a Bright Future Ahead of Us



# **Q1 2023 UPDATE**

### LATEST SEGMENT UPDATE

End Market

**Expectations** 

Ţ٩

Internal

Initiatives

Raw

**Materials** 



### Elektron

- Ongoing recovery in aerospace and automotive
- Expanded chemical kit volumes
- Destocking a headwind
- Soft demand for mag plate in Europe
- Qualification ahead of plan for alternative military magnesium supply
- Investment in growth-related engineering, R&D and capex
- Good availability in general
- New sources introduced
- Elevated basic chemicals costs

#### **Gas Cylinders**

- Ongoing recovery in aerospace
- SCBA and medical demand firm
- Destocking and project delays impacting Alternative Fuels
- Industrial demand uneven
- Further cost pass-through implemented Jan 1<sup>st</sup> and Apr 1<sup>st</sup>
- Reducing fixed costs; successful initiatives implemented in Q1 2023
- Good availability in general
- Moderating rise in carbon fiber prices
- Elevated aluminum costs

### **Toughening Aspects of Macro Environment**

## SALES PERFORMANCE BY END MARKET



	Y	ear-over-Y	ear Change	e	
	FY 2020	FY 2021	FY 2022	Q1 2023	Q1 2023 Commentary
<u>42%</u> Defense, First Response, & Healthcare	-6.4%	+5.9%	+5.6%	+32.3%	<ul> <li>Robust areas of Defense demand: military aerospace and chemical kits</li> <li>SCBA, medical O<sub>2</sub> and pharmaceutical also contribute to growth</li> </ul>
<u>26%</u> Transportation (Alternative Fuel, Aerospace, Automotive)	-14.7%	+27.0%	+13.6%	-10.4%	<ul> <li>Alternative Fuels soft with project delays</li> <li>Aerospace and automotive continue to perform well</li> </ul>
<u>32%</u> General Industrial	-18.0%	+15.5%	+20.4%	-8.2%	<ul> <li>Oil &amp; gas lower</li> <li>Photoengraving plate challenged by price competition in Europe</li> <li>Chemical catalysis and zirconium oxides strong</li> </ul>
TOTAL	-13.0%	+15.2%	+13.2%	+4.4%	

#### Strong DFR&H Partly Offset by Transportation and Industrial




# Q1 2023 FINANCIAL BRIDGE: CONSOLIDATED

#### Sales increased by 4.4% from prior year

- Price increases of \$10.0M offset rising inflation
- Volume contracted in both Elektron and Gas Cylinders
- FX headwind of \$2.3M due to USD strengthening year-over-year

#### EBITDA decreased by 29.8% from prior year

- Continued progress in passing through cost increases
- Adverse mix exacerbated the impact of volume reduction
- Headcount investment associated with growth also impacted profit performance



Inflation

Vol/Mix

Other

### **Cost Pass Through but Adverse Volume/Mix**

Q1 2023

Q1 2022

FX

Price

# Q1 2023: SEGMENT RESULTS



	Q1 2023	Q1 2022	Change	Q1 2023 Commentary
Elektron:				<ul> <li>Strong aerospace, healthcare, and chemical kit demand</li> </ul>
Sales	\$59.8	\$54.6	+9.5%	<ul> <li>Lower demand for higher margin products, including oil &amp; gas and photoengraving plate</li> </ul>
Adj. EBITDA	\$8.8	\$13.4	-34.3%	<ul> <li>Difficult year-over-year comparisons due to price leading inflation in Q1 2022</li> </ul>
				<ul> <li>Higher legal costs also impacted margin</li> </ul>
Gas Cylinders:				<ul> <li>Underlying revenue excluding FX increased year</li> </ul>
Sales	\$41.5	\$42.4	-2.1%	over year
				<ul> <li>Growth in aerospace, SCBA and medical offset by alternative fuels</li> </ul>
Adj. EBITDA	\$2.5	\$2.7	-7.4%	<ul> <li>Cost pass-through fully offset inflation</li> </ul>
				<ul> <li>Progressing on additional input cost recovery</li> </ul>

Focused on Execution amid Divergence in End Markets

CUSTOMER FIRST • INTEGRITY • ACCOUNTABILITY • INNOVATION • PERSONAL DEVELOPMENT • TEAMWORK

### **REITERATING 2023 EPS GUIDANCE**



2023 Guidance		Expectations
Sales Growth (incl. volume, price and FX)	4% - 7%	<ul> <li>Sales outlook tempered amid backdrop of mixed cyclical indicators</li> </ul>
Adjusted Diluted EPS	\$1.15 - \$1.35	• Focus on cost control to maintain profitability
Assumptions		
Free Cash Flow Conversion excl Exceptionals	100%	<ul> <li>Maintaining FCF Conversion target but goal pressured by elevated inventory costs</li> </ul>
<b>Operating Working Capital %</b> of Sales	23% - 25%	<ul> <li>Maintaining capital investment in long-term growth projects</li> </ul>
Сарех	\$12M - \$15M	
Tax Rate	~23%	<ul> <li>\$2.3M buyout of US Defined Benefit Pension plan successfully executed in Q1 2023; no</li> </ul>
Restructuring Cash Outlay	~\$5M	contributions expected to UK plan
Leverage and Liquidity (Ap	ril 2, 2023)	
Net Debt to LTM EBITDA	1.5x	
Liquidity	\$84.6M	

#### **Efficiency Initiatives Offset Tempered Sales Expectations**

Strategy Deployment Underpins 2025 \$2.00 Adj. EPS Goal

# LUXFER BUSINESS SYSTEM: STRATEGY DEPLOYMENT

#### Luxfer Business System

- > A critical tool to realize growth potential embedded in our business
- > Drives commonality and best practice in six critical segments
- Emphasis on near-term execution to **unlock sustainable growth**

### Q1 Update: Strategy Deployment

- Refreshed multi-year strategic planning process
- Aligns key objectives and initiatives with profitable growth
- Strong focus on Customer First and Innovation
- Balanced scorecard of metrics to monitor performance
- Timeline oriented towards our 2025 \$2.00 Adj. EPS goal
- Harnessing key tailwinds including Inflation Reduction Act, REPowerEU, and the ongoing aerospace and automotive recovery



**Our Pathway to** 

### LUXFER MDP



#### Luxfer Management Development Program

- > Organization-wide initiative to invest in Luxfer's emerging talent
- > Targeted at twenty professionals earlier in their careers
- > Focused on developing managerial, communication and leadership skills
- Supports high performance, retention and ultimately profitable growth





#### **Investing in Our Talent to Drive Profitable Growth**




# **APPENDICES**

Segment Financial Detail and Reconciliation of Non-GAAP Measures

# **Q1 2023: ELEKTRON SEGMENT RESULTS**





2023 Q1 2022 FX Price Inflation Volume/Mix Other Q1 202

#### CUSTOMER FIRST • INTEGRITY • ACCOUNTABILITY • INNOVATION • PERSONAL DEVELOPMENT • TEAMWORK

LUXFER



24

LUXFER

### CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)

		First Qu	
In millions, except share and per share data		2023	2022
Net sales	\$	101.3	
Cost of goods sold		(80.2)	(72.8)
Gross profit		21.1	24.2
Selling, general and administrative expenses		(12.5)	(10.7)
Research and development		(1.2)	(1.3)
Restructuring charges		(0.3)	(1.4)
Acquisition and disposal related costs		_	(0.2)
Operating income		7.1	10.6
Interest expense		(1.3)	(0.8)
Defined benefit pension (charge) / credit		(8.9)	0.4
(Loss) / income before income taxes		(3.1)	10.2
Credit / (provision) for income taxes		3.6	(2.5)
Net income from continuing operations		0.5	7.7
Net income / (loss) from discontinued operations	\$	— \$	\$ (0.1)
Net income	\$	0.5	\$ 7.6
Earnings / (loss) per share <sup>1</sup>			
Basic from continuing operations	\$	0.02	\$ 0.28
Basic from discontinued operations <sup>2</sup>	\$	- 9	\$
Basic	\$	0.02	0.28
Diluted from continuing operations	\$	0.02 \$	0.28
Diluted from discontinued operations <sup>2</sup>	\$	_ \$	s —
Diluted	\$	0.02	0.28
Weighted average ordinary shares outstanding			
Basic	26,	921,010	27,490,741
Diluted	27.	071,494	27,696,118

<sup>1</sup>The calculation of earnings per share is performed separately for continuing and discontinued operations. As a result, the sum of the two in any particular period may not equal the earnings-per-share amount in total.

<sup>2</sup>The loss per share for discontinued operations in the First Quarter of 2022 has not been diluted, since the incremental shares included in the weighted-average number of shares outstanding would have been anti-dilutive.

### **CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)**



		April 02,	De	cember 31
In millions, except share and per share data		2023		2022
Current assets				
Cash and cash equivalents	\$	1.8	\$	12.6
Restricted cash		0.3		0.3
Accounts and other receivables, net of allowances of \$0.5 and \$0.4, respectively	ý	74.2		67.8
Inventories		129.4		111.1
Current assets held-for-sale		7.8		9.3
Total current assets	\$	213.5	\$	201.1
Non-current assets				
Property, plant and equipment, net	\$	77.6	\$	77.7
Right-of-use assets from operating leases		19.2		19.8
Goodwill		66.5		65.6
Intangibles, net		12.4		12.5
Deferred tax assets		3.2		3.0
Investments and loans to joint ventures and other affiliates		0.3		0.4
Pensions and other retirement benefits		28.4		27.0
Total assets	\$	421.1	\$	407.1
Current liabilities				
Short-term debt	\$	25.0	\$	25.0
Accounts payable		39.3		37.8
Accrued liabilities		28.9		29.4
Taxes on income		2.7		1.8
Current liabilities held-for-sale		4.1		5.0
Other current liabilities		11.8		11.2
Total current liabilities	\$	111.8	\$	110.2
Non-current liabilities				
Long-term debt	\$	66.4	\$	56.2
Pensions and other retirement benefits		_		4.5
Deferred tax liabilities		11.4		9.9
Other non-current liabilities		17.5		19.0
Total liabilities	\$	207.1	\$	199.8
Shareholders' equity				
Ordinary shares of £0.50 par value; authorized 40,000,000 shares for 2023 and 2022; issued and outstanding 28,944,000 for 2023 and 2022	\$	26.5	s	26.5
Additional paid-in capital		221.7		221.4
Treasury shares		(21.2)		(20.4
Own shares held by ESOP		(1.0)		(1.0
Retained earnings		117.2		120.2
Accumulated other comprehensive loss		(129.2)		(139.4
Total shareholders' equity	\$	214.0	\$	207.3
Total liabilities and shareholders' equity	\$	421.1	ŝ	407.1

### CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) LUXFER

In millions		First Quarter 2023	2022
Operating activities			
Net income	\$	0.5 \$	7.6
Net (income) / loss from discontinued operations		_	0.1
Net income from continuing operations	\$	0.5 \$	7.7
Adjustments to reconcile net income to net cash used by operating activities			
Depreciation		3.1	3.5
Amortization of purchased intangible assets		0.2	0.2
Amortization of debt issuance costs		0.1	0.2
Share-based compensation charges		0.6	0.2
Deferred income taxes		1.2	0.1
Defined benefit pension charge / (credit)		8.9	(0.4)
Defined benefit pension contributions		(2.3)	_
Changes in assets and liabilities			
Accounts and other receivables		(2.3)	(12.2)
Inventories		(17.1)	(16.2)
Other current assets		1.5	(3.0)
Accounts payable		(2.4)	6.8
Accrued liabilities		(1.0)	3.4
Other current liabilities		(4.4)	2.0
Other non-current assets and liabilities		(1.0)	(1.6)
Net cash used by operating activities - continuing		(14.4)	(9.3)
Net cash provided by operating activities - discontinued		_	_
Net cash used by operating activities	\$	(14.4) \$	(9.3)
Investing activities			
Capital expenditures	\$	(2.0) \$	(1.0)
Net cash used by investing activities - continuing		(2.0)	(1.0)
Net cash used by investing activities - discontinued		_	—
Net cash used by investing activities	\$	(2.0) \$	(1.0)
Financing activities			
Net drawdown of long-term borrowings	\$	9.9 \$	26.7
Repurchase of own shares		(0.8)	(1.5)
Share-based compensation cash paid		(0.3)	(0.4)
Dividends paid		(3.5)	(3.4)
Net cash provided by financing activities	\$	5.3 \$	21.4
Effect of exchange rate changes on cash and cash equivalents Net increase	\$	0.3	(0.2)
	ð	(10.8) \$	10.9 6.4
Cash, cash equivalents and restricted cash; beginning of year		2.1	17.3
Cash, cash equivalents and restricted cash; end of the First Quarter		2.1	17.3
Supplemental cash flow information:			
Interest payments	\$	1.4 \$	0.8
Income tax receipts, net		(0.5)	(0.1)

### RECONCILIATION OF NON-GAAP FINANCIAL MEASURES: NET DEBT, OPERATING WORKING CAPITAL, OPERATING WORKING CAPITAL AS A % OF NET ANNUALIZED NET SALES, AND FREE CASH FLOW (UNAUDITED)



In millions	2017	2022	Q1 2021	Q2 2021	Q3 2021	Q4 2021	Q1 2022	Q2 2022	Q3 2022	Q4 2022	Q1 2023
Non-current debt	\$94.6	\$56.2	\$73.0	\$49.6	\$49.6	\$59.6	\$85.9	\$75.9	\$61.8	\$56.2	\$66.4
Current debt	19.2	25.0	-	-	-	-	-	-	25.0	25.0	25.0
Cash and cash equivalents	(12.6)	(12.6)	(31.8)	(10.1)	(15.1)	(6.2)	(17.2)	(5.3)	(11.2)	(12.6)	(1.8)
Net Debt	\$101.2	\$68.6	\$41.2	\$39.5	\$34.5	\$53.4	\$68.7	\$70.6	\$75.6	\$68.6	\$89.6
Accounts and other receivables, net of allowances	\$54.7	\$67.8	\$56.0	\$57.5	\$59.0	\$57.8	\$69.6	\$75.2	\$66.1	\$67.8	\$74.2
Inventories	69.1	111.1	75.6	77.3	80.6	90.5	105.9	104.7	111.6	111.1	129.4
Accounts payable	(32.6)	(37.8)	(27.7)	(28.9)	(30.7)	(31.7)	(37.8)	(34.0)	(27.9)	(37.8)	(39.3)
Accrued liabilities	(18.4)	(29.4)	(23.7)	(26.2)	(30.1)	(28.2)	(31.3)	(29.2)	(32.6)	(29.4)	(28.9)
Operating Working Capital	\$72.8	\$111.7	\$80.2	\$79.7	\$78.8	\$88.4	\$106.4	\$116.7	\$117.2	\$111.7	\$135.4
Net sales	\$348.0	\$423.4	\$85.2	\$99.0	\$91.2	\$98.7	\$97.0	\$109.5	\$100.2	\$116.7	\$101.3
Annualized net sales	NA	NA	\$340.8	\$396.0	\$364.8	\$394.8	\$388.0	\$438.0	\$400.8	\$466.8	\$405.2
Operating Working Capital as a % of Annualized Net Sales	NA	NA	23.5%	<b>20.</b> 1%	21.6%	22.4%	27.4%	26.6%	29.2%	23.9%	33.4%
Net Cash Provided by Operating Activities - Continuing	\$38.8	\$15.8	\$11.6	\$12.8	\$9.7	(\$8.1)	(\$9.3)	\$2.5	\$3.6	\$19.0	(\$14.4)
Capital Expenditures	(10.5)	(8.3)	(1.4)	(2.2)	(2.0)	(3.5)	(1.0)	(1.9)	(2.3)	(3.1)	(2.0)
Free Cash Flow	\$28.3	\$7.5	\$10.2	\$10.6	\$7.7	(\$11.6)	(\$10.3)	\$0.6	\$1.3	\$15.9	(\$16.4)

#### RECONCILIATION OF NON-GAAP FINANCIAL MEASURES: ADJUSTED NET INCOME FROM CONTINUING OPERATIONS, ADJUSTED EPS, ADJUSTED EBITDA, ADJUSTED EBITDA MARGIN, NET DEBT TO TRAILING 12 MONTHS ADJUSTED EBITDA<sup>1</sup>

In millions	2017	2022	Q1 2021	Q2 2021	Q3 2021	Q4 2021	Q1 2022	Q2 2022	Q3 2022	Q4 2022	Q1 2023
Net income from continuing operations	\$16.4	\$32.0	\$8.6	\$11.9	\$6.0	\$3.5	\$7.7	\$9.6	\$8.5	\$6.2	\$0.
Accounting charges relating to acquisitions and disposals of businesses:											
Unwind of discount on deferred consideration	0.2	-	-	-	-	-	-	-	-	-	
Amortization of acquired intangibles	1.3	0.7	0.2	0.2	0.3	0.2	0.2	0.2	0.2	0.1	0.2
Acquisition and disposal related costs	(1.3)	0.3	0.2	0.7	0.6	-	0.2	0.1	-	-	
Defined benefit pension charge / (credit)	(4.2)	(0.1)	(0.6)	(0.6)	(0.6)	(0.5)	(0.4)	(0.3)	(0.2)	0.8	8.9
Restructuring charges	8.4	1.9	1.4	0.2	0.5	4.1	1.4	0.3	0.3	(0.1)	0.3
Impairment charges	3.7	-	-	-	-	-	-	-	-	-	
Other charges	5.8	-	1.1	-	-	-	-	-	-	-	
Share-based compensation charges	2.2	2.5	0.5	0.9	0.8	0.6	0.2	0.7	0.9	0.7	0.6
Tax impact of defined benefit pension settlement											(4.9
Other non-recurring tax items <sup>2</sup>	(2.0)	-	-	(2.2)	-	0.3	-	-	-	-	
Income tax on adjusted items	(3.1)	0.1	(0.5)	(0.9)	(0.4)	(0.3)	(0.1)	(0.5)	(0.1)	0.8	(0.2
Adjusted net income from continuing operations	\$27.4	\$37.4	\$10.9	\$10.2	\$7.2	\$7.9	\$9.2	\$10.1	\$9.6	\$8.5	\$5.4
Add back:											
Tax impact of defined benefit pension settlement											4.9
Other non-recurring tax items	2.0	-	-	2.2	-	(0.3)	-	-	-	-	
Income tax on adjusted items	3.1	(0.1)	0.5	0.9	0.4	0.3	0.1	0.5	0.1	(0.8)	0.2
Provision for income taxes	3.3	9.0	2.3	(0.6)	1.9	1.8	2.5	2.4	2.3	1.8	(3.6)
Net finance costs	6.3	3.9	0.8	0.8	0.8	0.7	0.8	0.9	1.0	1.2	1.3
Adjusted EBITA	42.1	50.2	14.5	13.5	10.3	10.4	12.6	13.9	13.0	10.7	8.2
Loss on disposal of property, plant, and equipment	-	-	-	-	-	-	-	(0.2)	-	0.2	
Depreciation	15.1	12.9	3.2	3.8	3.5	4.2	3.5	3.2	3.1	3.1	3.1
Adjusted EBITDA	57.2	63.1	17.7	17.3	13.8	14.6	16.1	16.9	16.1	14.0	11.3
Last 12 months adjusted EBITDA	\$57.2	\$63.1				\$63.4	\$61.8	\$61.4	\$63.7	\$63.1	\$58.3
Net sales	\$348.0	\$423.4	\$85.2	\$99.0	\$91.2	\$98.7	\$97.0	\$109.5	\$100.2	\$116.7	\$101.3
Adjusted EBITDA margin	16.4%	14.9%	20.8%	17.5%	15.1%	14.8%	16.6%	15.4%	16.1%	12.0%	11.2%
Net Debt	\$101.2	\$68.6	\$41.2	\$39.5	\$34.5	\$53.4	\$68.7	\$70.6	\$75.6	\$68.6	\$89.6
Net Debt to last 12 months adjusted EBITDA	0.01.2	1.1x	<b>\$</b> 11.2	<b>\$0010</b>	<b>\$0 110</b>	0.8x	1.1x	1.2x	1.2x	1.1x	1.5
	1.04					0.07		1.24	1.24		1.0/
Weighted average diluted ordinary shares outstanding	26,723,981	27,541,202	28,057,323	28,131,785	28,033,732	27,929,690	27,696,118	27,703,217	27,525,314	27,482,347	27,071,49
Adjusted earnings per ordinary share <sup>3</sup>											
Diluted earnings per ordinary share	\$0.61	\$1.16	\$0.31	\$0.42	\$0.21	\$0.13	\$0.28	\$0.35	\$0.31	\$0.23	\$0.02
Impact of adjusted items	\$0.42	\$0.20	\$0.08	(\$0.06)	\$0.05	\$0.15	\$0.05	\$0.01	\$0.04	\$0.08	\$0.18
Adjusted diluted earnings per ordinary share	\$1.03	\$1.36	\$0.39	\$0.36	\$0.26	\$0.28	\$0.33	\$0.36	\$0.35	\$0.31	\$0.20

<sup>1</sup>From continuing operations unless otherwise stated.

<sup>2</sup>Other non-recurring tax items in 2021 periods represent the impact of the enacted U.K. tax rate change (from 19% to 25% with effect from April 2023) on deferred tax assets related to our U.K. defined benefit pension plan.

<sup>3</sup>For the purpose of calculating diluted earnings per share, the weighted average number of ordinary shares outstanding during the financial year has been adjusted for the dilutive effects of all potential ordinary shares and share options granted to employees, except where there is a loss in the period, then no adjustment is made.

### RECONCILIATION OF NON-GAAP FINANCIAL MEASURES: RETURN ON INVESTED CAPITAL (ROIC)<sup>1</sup>



	Q1 2021	Q2 2021	Q3 2021	Q4 2021	Q1 2022	Q2 2022	Q3 2022	Q4 2022	Q1 2023
EBITA	\$14.5	\$13.5	\$10.3	\$10.4	\$12.6	\$13.7	\$13.0	\$10.7	\$8.2
Notional tax	(3.6)	(2.8)	(2.5)	(3.5)	(3.1)	(2.7)	(2.8)	(2.4)	(9.5
EBITA after Notional Tax	\$10.9	\$10.7	\$7.8	\$6.9	\$9.5	\$11.0	\$10.2	\$8.3	(\$1.3
Trailing 12 Month EBITA after Notional Tax	\$30.6	\$35.2	\$38.2	\$36.3	\$34.9	\$35.2	\$37.6	\$39.0	\$28.
Total debt	\$73.0	\$49.6	\$49.6	\$59.6	\$85.9	\$75.9	\$86.8	\$81.2	\$91.·
Cash and cash equivalents	(31.8)	(10.1)	(15.1)	(6.2)	(17.2)	(5.3)	(11.2)	(12.6)	(1.8
Total equity	178.9	188.2	186.7	209.1	206.6	205.5	195.3	207.3	214.
Held-for-sale assets, net	(13.4)	(13.6)	(13.0)	(3.4)	(3.2)	(3.1)	(3.0)	(3.1)	(2.5
Invested Capital	\$206.7	\$214.1	\$208.2	\$259.1	\$272.1	\$273.0	\$267.9	\$272.8	\$301.
Trailing 12 Month Average Invested Capital	\$211.0	\$207.7	\$206.8	\$222.0	\$238.4	\$253.1	\$268.0	\$271.5	\$278.
	14.5%	17.0%	18.5%	16.3%	14.6%	13.9%	14.0%	4.4.40/	40.40
Return on Invested Capital	14.3%	17.0%	10.3%	10.3%	14.0%	13.9%	14.0%	14.4%	10.1%
Adjusted net income from continuing operations	\$10.9	\$10.2	\$7.2	\$7.9	\$9.2	\$10.1	\$9.6	\$8.5	\$5.4
Adjusted net income from continuing operations Provision for income taxes	\$10.9 \$2.3	\$10.2 (\$0.6)	\$7.2 \$1.9	\$7.9 \$1.8	\$9.2 \$2.5	\$10.1 \$2.4	\$9.6 \$2.3	\$8.5 \$1.8	• -
	,		·	•	• -	•	•		(\$3.6
Provision for income taxes	\$2.3	(\$0.6)	\$1.9	\$1.8	\$2.5	\$2.4	\$2.3	\$1.8	(\$3.6 5.
Provision for income taxes Income tax on adjustments to net income Adjusted income tax charge	\$2.3 0.5	(\$0.6) 3.1	\$1.9 0.4	\$1.8 -	\$2.5 0.1	\$2.4 0.5	\$2.3 0.1	\$1.8 (0.8)	(\$3.6 <u>5</u> . \$1.
Provision for income taxes Income tax on adjustments to net income Adjusted income tax charge Adjusted profit before taxation	\$2.3 0.5 \$2.8	(\$0.6) <u>3.1</u> \$2.5	\$1.9 0.4 \$2.3	\$1.8 - \$1.8	\$2.5 0.1 \$2.6	\$2.4 0.5 \$2.9	\$2.3 0.1 \$2.4	\$1.8 (0.8) \$1.0	(\$3.6 <u>5.</u> \$1. \$6.
Provision for income taxes Income tax on adjustments to net income Adjusted income tax charge Adjusted profit before taxation	\$2.3 0.5 \$2.8 \$13.7	(\$0.6) <u>3.1</u> \$2.5 \$12.7	\$1.9 0.4 \$2.3 \$9.5	\$1.8 	\$2.5 0.1 \$2.6 \$11.8	\$2.4 0.5 \$2.9 \$13.0	\$2.3 0.1 \$2.4 \$12.0	\$1.8 (0.8) \$1.0 \$9.5	(\$3.6 5. \$1. \$6. 21.79
Provision for income taxes Income tax on adjustments to net income Adjusted income tax charge Adjusted profit before taxation Adjusted effective tax rate	\$2.3 0.5 \$2.8 \$13.7 20.4%	(\$0.6) <u>3.1</u> \$2.5 \$12.7 19.7%	\$1.9 0.4 \$2.3 \$9.5 24.3%	\$1.8 \$1.8 \$9.7 18.6%	\$2.5 0.1 \$2.6 \$11.8 22.0%	\$2.4 0.5 \$2.9 \$13.0 22.3%	\$2.3 0.1 \$2.4 \$12.0 20.0%	\$1.8 (0.8) \$1.0 \$9.5 10.5%	(\$3.6 5. \$1. \$6. 21.79 \$8.
Provision for income taxes Income tax on adjustments to net income Adjusted income tax charge Adjusted profit before taxation Adjusted effective tax rate EBITA Adjusted notional tax	\$2.3 0.5 \$2.8 \$13.7 20.4% \$14.5	(\$0.6) <u>3.1</u> \$2.5 \$12.7 19.7% \$13.5	\$1.9 0.4 \$2.3 \$9.5 24.3% \$10.3	\$1.8 \$1.8 \$9.7 18.6% \$10.4	\$2.5 0.1 \$2.6 \$11.8 22.0% \$12.6	\$2.4 0.5 \$2.9 \$13.0 22.3% \$13.7	\$2.3 0.1 \$2.4 \$12.0 20.0% \$13.0	\$1.8 (0.8) \$1.0 \$9.5 10.5% \$10.7	(\$3.6 <u>5.</u> \$1. \$6. 21.79 \$8. (1.8
Provision for income taxes Income tax on adjustments to net income Adjusted income tax charge Adjusted profit before taxation Adjusted effective tax rate EBITA	\$2.3 0.5 \$2.8 \$13.7 20.4% \$14.5 (3.0)	(\$0.6) <u>3.1</u> \$2.5 \$12.7 19.7% \$13.5 (2.7)	\$1.9 0.4 \$2.3 \$9.5 24.3% \$10.3 (2.5)	\$1.8 \$1.8 \$9.7 18.6% \$10.4 (1.9)	\$2.5 0.1 \$2.6 \$11.8 22.0% \$12.6 (2.8)	\$2.4 0.5 \$2.9 \$13.0 22.3% \$13.7 (3.1)	\$2.3 0.1 \$2.4 \$12.0 20.0% \$13.0 (2.6)	\$1.8 (0.8) \$1.0 \$9.5 10.5% \$10.7 (1.1)	\$5.4 (\$3.6 5. \$1.4 \$6.4 21.79 \$8.2 (1.8 \$6.4 <b>\$37.0</b>

